Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Bao Pharmaceuticals CoHKSE:02659 +0.25%9 PS Ratio is 96.61 as of Aug. 27, 2026, which is 76% below its 10-year median of 394.52. GuruFocus rates HKSE:02659 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 931 Biotechnology companies, Shanghai Bao Pharmaceuticals Co ranks worse than 84% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Shanghai Bao Pharmaceuticals Co's share price is HK$15.94.
Shanghai Bao Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17. Hence, Shanghai Bao Pharmaceuticals Co's PS Ratio for today is 96.61.
Good Sign:
Shanghai Bao Pharmaceuticals Co Ltd stock PS Ratio (=85.03) is close to 1-year low of 85.03.
The historical rank and industry rank for Shanghai Bao Pharmaceuticals Co's PS Ratio or its related term are showing as below:
HKSE:02659'
s PS Ratio Range Over the Past 10 Years
Min: 85.08 Med: 394.52 Max: 3922.5
Current: 96.61
During the past 3 years, Shanghai Bao Pharmaceuticals Co's highest PS Ratio was 3922.50. The lowest was 85.08. And the median was 394.52.
HKSE:02659's PS Ratio is ranked worse than 84% of 931
companies
in the Biotechnology industry
Industry Median: 9.49
vs HKSE:02659: 96.61
Shanghai Bao Pharmaceuticals Co (HKSE:02659) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Shanghai Bao Pharmaceuticals Co PS Ratio Related Terms
Shanghai Bao Pharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Bao Pharmaceuticals Co PS Ratio Chart
Shanghai Bao Pharmaceuticals Co Annual Data
Trend
Dec23
Dec24
Dec25
PS Ratio
0.00
0.00
414.71
Shanghai Bao Pharmaceuticals Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PS Ratio
0.00
0.00
0.00
0.00
414.71
HKSE:02659 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Shanghai Bao Pharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Bao Pharmaceuticals Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Bao Pharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Bao Pharmaceuticals Co's PS Ratio falls into.
Shanghai Bao Pharmaceuticals Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Shanghai Bao Pharmaceuticals Co's Share Price of today is HK$15.94.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Bao Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a PS Ratio of 96.61 as of Aug. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. This is 76% below median its historical median of 394.52. Over the past decade, Shanghai Bao Pharmaceuticals Co's PS Ratio has ranged from 85.08 to 3,922.50. According to the industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #782 out of 931 companies in the Biotechnology industry, placing it in the top 84%.
Is Shanghai Bao Pharmaceuticals Co's PS Ratio too high?
Shanghai Bao Pharmaceuticals Co's current PS Ratio of 96.61 is 76% below median its 10-year median of 394.52. Over the past 10 years, this metric has ranged from a low of 85.08 to a high of 3,922.50. The Biotechnology industry median PS Ratio is 9.49. Shanghai Bao Pharmaceuticals Co's value of 96.61 is 918% above this industry median. Based on the distribution chart, Shanghai Bao Pharmaceuticals Co ranks #782 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Bao Pharmaceuticals Co ranks #782 out of 931 companies for PS Ratio. This places Shanghai Bao Pharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 9.49. Shanghai Bao Pharmaceuticals Co's value of 96.61 is 918% above this benchmark. Historically, Shanghai Bao Pharmaceuticals Co's own PS Ratio has ranged from 85.08 to 3,922.50 over the past decade. While the company's 10-year median is 394.52 vs. the industry median of 9.49, Shanghai Bao Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Bao Pharmaceuticals Co's current PS Ratio of 96.61 is 918% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai Bao Pharmaceuticals Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Bao Pharmaceuticals Co's current PS Ratio is 96.61, which is 76% below median its own 10-year median of 394.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current PS Ratio of 96.61. The current PS Ratio is 96.61, which is 76% below median its 10-year median of 394.52 and 918% above the Biotechnology industry median of 9.49. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current PS Ratio is 96.61 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score
Get the complete analysis for HKSE:02659
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02659 has been successfully added to your 
